Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maze Therapeutics (MAZE) Total Liabilities (2024 - 2026)

Maze Therapeutics' Total Liabilities history spans 3 years, with the latest figure at $78.0 million for Q1 2026.

  • On a quarterly basis, Total Liabilities rose 91.33% to $78.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $78.0 million, a 91.33% increase, with the full-year FY2025 number at $42.2 million, down 3.38% from a year prior.
  • Total Liabilities hit $78.0 million in Q1 2026 for Maze Therapeutics, up from $42.2 million in the prior quarter.
  • Over the last five years, Total Liabilities for MAZE hit a ceiling of $403.7 million in Q1 2024 and a floor of $40.8 million in Q1 2025.
  • Historically, Total Liabilities has averaged $137.7 million across 3 years, with a median of $43.6 million in 2024.
  • Biggest five-year swings in Total Liabilities: crashed 89.9% in 2025 and later skyrocketed 91.33% in 2026.
  • Tracing MAZE's Total Liabilities over 3 years: stood at $43.6 million in 2024, then decreased by 3.38% to $42.2 million in 2025, then skyrocketed by 85.03% to $78.0 million in 2026.
  • Business Quant data shows Total Liabilities for MAZE at $78.0 million in Q1 2026, $42.2 million in Q4 2025, and $42.6 million in Q3 2025.